<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855400</url>
  </required_header>
  <id_info>
    <org_study_id>CMN/ELA</org_study_id>
    <secondary_id>EudraCT number: 2006-003096-12</secondary_id>
    <secondary_id>ISCIII: EC07/90762</secondary_id>
    <nct_id>NCT00855400</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>CMN/ELA</acronym>
  <official_title>Phase I/II Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Morales Meseguer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Diógenes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to asses the feasibility and the security of the
      intraspinal infusion of autologous bone marrow stem cells for the treatment of Amyotrophic
      Lateral Sclerosis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Amyotrophic Lateral Sclerosis (ALS) typically endure a progressive paralysis
      due to the continued loss of motoneurons that leads them to death in less than 5 years. No
      treatment has changed its natural history. Intraspinal injections of bone marrow mononuclear
      cells (MNC) have been able to ameliorate the course of ALS in murine models, acting as pumps
      of trophic factors that keep the motoneurons functional. We have designed a phase I/II
      clinical trial to check the feasibility of this approach in humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>Every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALS-FRS, MRC and Norris scales</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of adverse events</measure>
    <time_frame>Every week / month depending on the study phase</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laminectomy and bone marrow stem cells transplantation</intervention_name>
    <description>T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation</description>
    <arm_group_label>Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone marrow cells collection</intervention_name>
    <description>Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.</description>
    <arm_group_label>Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnose established following the World Federation of Neurology criteria

          -  More than 6 and less than 36 months of evolution of the disease

          -  Medullar onset of the disease

          -  More than 20 and less than 65 years old

          -  Forced Vital Capacity equal or superior to 50%

          -  Total time of oxygen saturation &lt;90% inferior to 2% of the sleeping time

          -  Signed informed consent

        Exclusion Criteria:

          -  Neurological or psychiatric concomitant disease

          -  Need of parenteral or enteral nutrition through percutaneous endoscopic gastrostomy or
             nasogastric tube

          -  Concomitant systemic disease

          -  Treatment with corticosteroids, immunoglobulins or immunosuppressors during the last
             12 months

          -  Inclusion in other clinical trials

          -  Unability to understand the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Maria Moraleda Jiménez, M.D. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2009</study_first_submitted>
  <study_first_submitted_qc>March 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2009</study_first_posted>
  <last_update_submitted>December 1, 2010</last_update_submitted>
  <last_update_submitted_qc>December 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Javier Júdez Gutiérrez</name_title>
    <organization>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</organization>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Autologous</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

